Eli Lilly (LLY)Rep. Byron Donalds (FL19) disclosed a purchase $1K–$15K
Rep. Byron Donalds (FL19) disclosed a purchase of Eli Lilly in the $1K–$15K range.
- $1,001–$15,000
- Reported range · official band, not an exact amount
- 41 days
- Disclosure lag
- Traded
- Apr 2, 2026
- Disclosed
- May 13, 2026
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Jan 16, 2026CongressDisclosed sale of LLY — reported range $1,001 - $15,000
- Feb 4, 2026Company filing · Form 8-K · ResultsReported its results
- Feb 9, 2026CongressDisclosed sale of LLY — reported range $1,001 - $15,000
- Feb 13, 2026CongressDisclosed sale of LLY — reported range $1,001 - $15,000
- Feb 26, 2026CongressDisclosed purchase of LLY — reported range $1,001 - $15,000
- Mar 13, 2026CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
- Mar 26, 20265% stakeThe Vanguard Group reported a passive stake (13G)
- Mar 27, 2026CongressDisclosed sale of LLY — reported range $1,001 - $15,000
- Apr 1, 2026FDAFDA drug approval: Foundayo
- Apr 2, 2026 · this disclosureCongressDisclosed purchase of LLY — reported range $1,001 - $15,000
What came next
- Apr 2, 2026CongressDisclosed purchase of LLY — reported range $1,001 - $15,000
- Apr 8, 2026CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
- Apr 14, 2026CongressDisclosed purchase of LLY — reported range $1,001 - $15,000
- Apr 20, 20265% stakeLILLY ENDOWMENT, INC. reported a passive stake (13G) of 9.7%
- Apr 30, 2026Company filing · Form 8-K · ResultsReported its results
- May 1, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 6.5%
- May 6, 2026Insider · 1 personInsiders: 2 sales (~$15.8M)
- May 15, 2026Federal contract · $52K obligatedDepartment of Veterans Affairs awarded Eli Lilly: $52K obligated to date
- Jun 9, 2026FDAFDA drug approval: Ebglyss
- Jun 10, 2026Insider · Their largest sale since 2022Officer sold ~$2.88M of LLY shares in the open market
- Jun 10, 2026Congress · 1 personMembers of Congress: 2 purchases
- Jul 10, 2026CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
- Jul 13, 2026FDAFDA drug approval: Verzenio
- Jul 14, 2026FDAFDA drug approval: Retevmo
- Jul 14, 2026FDAFDA drug approval: Retevmo
- Jul 23, 20265% stakeLILLY ENDOWMENT, INC. reported a passive stake (13G) of 9.6%
How to read House Clerk periodic transaction report
The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.
Full guide: What is the STOCK Act?
What else is on file for Eli Lilly
For Eli Lilly, OQRO holds 7 insider filings (SEC Form 4 or Form 144), 5 Congress trade reports, 189 fund holdings reports (13F) and 1 federal contract award dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its LLY page.
Other recent filings by Rep. Byron Donalds (FL19)
- House Clerk periodic transaction report at Howmet Aerospace (HWM)Sep 15, 2026
- House Clerk periodic transaction report at Howmet Aerospace (HWM)Sep 15, 2026
- House Clerk periodic transaction report at Netflix (NFLX)Sep 15, 2026
- House Clerk periodic transaction report at Netflix (NFLX)Sep 15, 2026
- House Clerk periodic transaction report at Parker Hannifin (PH)Sep 15, 2026
The full history of Rep. Byron Donalds (FL19) is on the profile page.
How this filing works
Other disclosures at Eli Lilly
- SEC Form 144Oct 7, 2026
- USAspending.gov award recordSep 1, 2026
- SEC Form 13F-HRAug 26, 2026
- SEC Form 13F-HRAug 25, 2026
- SEC Form 4Aug 18, 2026
- SEC Form 13F-HRAug 18, 2026
Everything OQRO holds on this company is on its LLY page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO Pro is a paid subscription. You see the price before you pay
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
